Enhancement of anticancer effects of radiation and conventional anticancer agents by a quinolinone derivative, vesnarinone: Studies on human gastric cancer tissue xenografts in nude mice

Anticancer Research

Volumn 18, Issue 1 A, 1998, Pages 405-412

  Kawai, Kazuyoshi ^a   Konishi, Yasue ^a   Izumi, Kazunari ^a   Sato, Mitsunobu ^b   Adachi, Masakazu ^a,c   Hozumi, Motoo ^c  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c JAPAN IMMUNORESEARCH LABORATORIES   (Japan)

Author keywords

Apoptosis; Cancer; Differentiation; Gastric; Radiation; Tumour suppression; Vesnarinone

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; PICIBANIL; PIPERANOMETOZINE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STOMACH CANCER; TUMOR CELL; TUMOR SUPPRESSOR GENE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL DIVISION; COMBINED MODALITY THERAPY; DRUG SYNERGISM; FLUOROURACIL; GENES, P53; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PICIBANIL; QUINOLINES; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; X-RAYS;

EID: 0031945967     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Feldman A M, Bristow M R, Parmley, W W, Carson P E, Pepine C J, Gilbert E M, Strobeck J E, Hendrix G E, Powers E R, Bain R P and White B G: Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 329: 149-155, 1993.
2. Nakai S, Kawai K, Aihara K Fujita F, Fujita M, Fujita M, Sakamoto Y and Adachi M: Vesnarinone(3, 4-dihydro-6-[4-(3, 4-dimethoxy-benzoyl)-1-piperazinyl]-2(1H)-quinolinone) as an antitumour agent with differentiation or apoptosis inducing activity in human cancer xenografts in nude mice. Proceedings of 85 th Annual Meeting of the American Association for Cancer Research 35: 404, 1994.
3. Kumakura T, Takase K, Terada N and Erwin W G: Vesnarinone inhibits nucleoside and nucleobase transport. Life Science 57: 78-81, 1995.
4. Maruyama I, Maruyama Y, Nakajima T, Kitajima I, Osame M, Zhao J-Q, Chen S Y, Nakai S, Ikeda M, Yabuuchi Y and Adachi M: Vesnarinone inhibits production of HIV-I in cultured cells. Biochem Biophys Res Commun 195: 1264-1271, 1993.
5. Yokozaki H, Ito R, Oda N, Semba S and Tahara E: Antiproliferative effect of vesnarinone on human gastric cancer cell line. Proceeding of the Eighth International Conference of the International Society of Differentiation(ISD) "Developmental Biology, Differentiation and Cancer:Toward 21st Century": p227, 1994.
6. Visakorpi T, Kallinoiemi O P, Heikkinen A T, Koivula T. and Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883-887, 1992.
7. Hsu S M, Ralne L and Franger H: Use of avidine-biotin peroxidase complex(ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody(PAP) procedures. J Histochem Cytochem 29: 577-580, 1981.
8. Gavrieli Y, Sherman Y and Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
9. y antigen expression is correlated with apoptosis (programmed cell death). Glycobiology 3: 381-390, 1993.
10. Sato M, Yoshida H, Yura Y, Azuma M, Iga H, Kaji R, Bando T, Yanagawa T and Takegawa T: The primary therapy of oral squamous cell carcinoma by UFT and OK-432 in combination with radiotherapy. Biotherapy 6: 108-111, 1992.
11. y antigen expression in treatment with differentiation-inducing agent, vesnarinone, of a patient with salivary adenoid cystic carcinoma. Apoptosis 2: 106-113, 1997.
12. Weinberg R: Tumour suppressor genes. Science 254:1138-1146, 1991.
13. Unger C, Kress S, Buchmann A and Schwartz M: γ -irradiation-induced micronuclei from mouse hepatoma cells accumulate high levels of the tumour suppressor protein p53. Cancer Research 54: 3651-3655, 1994.
14. El-Deiry W S, Tokino T, Velculescu V E, Levy D B, Parsons R, Trent J M, Lin D, Mercer W E, Kinzer K W and Vogelstein B: WAF-1, a potential mediator of p53 tumour suppression. Cell 75: 817-825, 1993.
15. Harper J W, Adami G R, Wei N, Keyomarsi K and Elledge S J: The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin dependent kinases. Cell 75: 805-816, 1993.
16. Waga S, Hannon G J, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.